Christopher G. Hayes - Mar 1, 2023 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
Chief Legal Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
VRCA
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
4
Date filed
3/3/2023, 03:25 PM
Previous filing
Jul 11, 2022
Next filing
Jul 25, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Employee Stock Option (right to buy) Award $0 +135K $0.00 135K Mar 1, 2023 Common Stock 135K $7.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.